Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on Merck & Company (MRK – Research Report), reducing the price ...

In a report released yesterday, Evan Seigerman from BMO Capital maintained a Buy rating on Merck & Company (MRK – Research Report), ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Merck’s stock fell Thursday morning, despite the company beating profit and sales estimates for the third quarter.

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health business.

The pharmaceutical company posted revenue of $16.66 billion in the period, also topping Street forecasts. Six analysts surveyed by Zacks expected $16.55 billion. Merck expects full-year earnings in ...

Oct 31 (Reuters) - Merck & Co (MRK.N), opens new tab ... and scuttles hospital deals with international pharmaceutical companies. The company expects Gardasil shipments to its partner Zhifei ...

Merck's overall pharmaceutical sales in China fell 40% to $996 million in the third quarter. "Outside of China, we're seeing strong growth," CEO Davis said, adding that the company has seen ...

Pharmaceutical giant Merck (NYSE: MRK) is recognized for its ... The main headwind preventing even stronger growth is weak sales of the company's Gardasil vaccine against human papillomavirus ...

Merck & Co. Inc.’s stock fell 3% Thursday, after the drug company beat profit and sales estimates for the third quarter, but ...

In this case, Merck narrowed its forecast for annual revenue ... The main headwind preventing even stronger growth is weak sales of the company's Gardasil vaccine against human papillomavirus ...

Oct 23 (Reuters) - Merck (MRK.N), opens new tab has acquired ... New Haven, Connecticut-based Modifi is a pre-clinical stage company, which develops cancer therapies that aim to selectively ...